Andra AP fonden Makes New $753,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Andra AP fonden acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,100 shares of the biopharmaceutical company's stock, valued at approximately $753,000.

Other large investors have also modified their holdings of the company. Truist Financial Corp acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $474,000. Gilbert & Cook Inc. lifted its position in shares of Alnylam Pharmaceuticals by 7.7% during the 4th quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company's stock worth $850,000 after buying an additional 317 shares during the period. Jump Financial LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $1,396,000. QRG Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $211,000. Finally, Dimensional Fund Advisors LP grew its position in Alnylam Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 267,034 shares of the biopharmaceutical company's stock valued at $51,126,000 after acquiring an additional 15,123 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $3.54 during trading hours on Friday, reaching $265.27. The company had a trading volume of 437,517 shares, compared to its average volume of 894,955. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The company has a 50 day moving average of $258.53 and a 200 day moving average of $194.56. The firm has a market cap of $34.06 billion, a price-to-earnings ratio of -98.98 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. Alnylam Pharmaceuticals's quarterly revenue was up 107.0% on a year-over-year basis. During the same quarter last year, the business posted ($2.21) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ALNY. Evercore ISI boosted their target price on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, June 25th. Cantor Fitzgerald restated a "neutral" rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday. Needham & Company LLC upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Finally, Bank of America increased their price target on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $279.14.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company's stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the business's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the firm's stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 103,148 shares of company stock worth $25,658,824. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.